Efficacy of tandospirone in treating functional dyspepsia accompanied by anxiety and depression and its influence on quality of life

Abstract

Abstract:

AIM: To observe the clinical efficacy of tandospirone in the treatment of functional dyspepsia (FD) accompanied by anxiety and depression and its influence on quality of life. METHODS: Ninety-eight cases with FD accompanied by anxiety and depression were randomly divided into treatment group and control group (n=49). Patients of control group were treated with oral pantoprazole and mosapride. On the basis of control group, the treatment group was given oral tandospirone for four weeks. The therapeutic effect and adverse effects were observed and compared in both groups. RESULTS: Compared with before treatment, the scores of FD symptoms, Hamilton Rating Scale for Despression (HAMD) and Hamilton Anxiety Scale (HAMA) in treatment group decreaed significantly after treatment, while the score of Functional Digestive Disorders Quality of Life Questionnaire (FDDQL) increased significantly (all P<0.01); the decrease of FD symptoms,HAMD,HAMA scores and the increase of FDDQL scores of treatment group were greater than those of control group (all P<0.01). The total effective rate of treatment group was significantly higher than that of control group (87.5% vs. 63.3%, χ²=6.49, P<0.05). There was no obvious adverse effect recurred in both groups. CONCLUSION: Tandospirone is a safe and effective drug for FD accompanied by anxiety and depression; it can effectively improve the symptoms of anxiety, depression and quality of life of patients.

Key words: functional dyspepsia, tandospirone, anxiety, depression, quality of life

CLC Number:

GONG Xiaobing, LI Shuzhen, HUANG Yesheng, MA Yan, LIU Yonggang, JIANG Yabin, YANG Jianquan. Efficacy of tandospirone in treating functional dyspepsia accompanied by anxiety and depression and its influence on quality of life[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 664-667.

References

［1］Ohara S, Kawano T, Kusano M, et al. Survey on the prevalence of GERD and FD based on the Montreal definition and the Rome III criteria among patients presenting with epigastric symptoms in Japan［J］. J Gastroenterol, 2011, 46(5): 603-611.
［2］陈仕武, 陈刚, 张晓, 等. 功能性消化不良抑郁、焦虑的发生情况及其对生活质量和疗效的影响［J］. 临床军医杂志, 2009, 37(6): 378-381.
［3］杜波，张鸿燕. 希德［J］. 中国新药杂志，2005，14（5）：639-641.
［4］张明园，主编. 精神科评定量表手册［M］.2版. 长沙：湖南科学技术出版社，2003：121-141.
［5］Buzás GM. Assessment of quality of life in functional dyspepsia. validation of a questionnaire and its use in clinical practice［J］. Orv Hetil, 2004, 145(13):687-692.
［6］杨云英，陈新林，陈玉琴，等. 功能性消化不良患者生存质量调查［J］. 护理学报，2014，21（3）：34-36.
［7］上海黛力新临床协作组. 氟哌噻吨美利曲辛联合多潘立酮治疗伴有焦虑抑郁状态的功能性消化不良患者的疗效研究［J］. 中华消化杂志，2013，33（7）：441-445.
［8］赵丹，毛华. 功能性消化不良病理生理机制研究进展［J］. 中华临床医师杂志（电子版），2014，8（15）：2880-2882.
［9］田虹，周汉建，戈兰，等.功能性消化不良患者焦虑和抑郁调查分析［J］. 广东医学，1999，20（11）：858-859.
［10］Brun R, Kuo B. Functional dyspepsia［J］. Therap Adv Gastroenterol, 2010, 3(3): 145-164.
［11］Gwee KA, Bak YT, Ghoshal UC, et al. Asian consensus on irritable bowl syndrome［J］. J Gastroenterol Hepatol, 2010, 25: 1189-1205.
［12］刘会民. 坦度螺酮的临床应用进展［J］. 天津药学，2014，26(4)：39-41.
［13］陈红生. 枸橼酸坦度螺酮辅助治疗功能性消化不良的疗效分析［J］. 中国医师进修杂志，2012，35( 22) : 28-30.
［14］熊小强，陈焕清，李楚强，等. 坦度螺酮治疗伴有焦虑的功能性消化不良的临床研究［J］. 国际医药卫生导报，2012，18 ( 22) : 3273-3275.
［15］陈洪英.帕罗西汀治疗功能性消化不良的临床效果［J］. 四川医学，2014，36( 10) : 1309-1311.

[1]	ZHANG Taotao, SU Wenxiu, TIAN Limin. Research progress on the relationship between subclinical hypothyroidism and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 954-960.
[2]	WU Xiongzhi, WANG Xuan, XU Siqi, JU Xia, WANG Shengbin, CHEN Yongquan. A comparative investigation of the impact of oral midazolam solution and dexmedetomidine nasal spray on preoperative anxiety in pediatric patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 666-670.
[3]	HE Teng, XU Xiangyang, XU Xiangqing, LIU Cunming, YANG Chun. Ketamine for depression treatment: past, present, and future [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1125-1132.
[4]	WANG Yeqing, WANG Yuhong, LIU Jian, ZHAO Hongqing, ZOU Manshu. Research progress of relevance between cholecystokinin and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 672-679.
[5]	CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
[6]	YANG Shitao, ZHU Yihong, TANG Wenxin. Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 937-942.
[7]	GE Wei, SHENG Wenyan, XU Qibing, LI Qiushi, SU Lingya, WU Shuangqing. Effects of SSRI antidepressant sertraline on ocular surface function in patients with postpartum depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 440-446.
[8]	FENG Rui, ZHANG Jiali, HE Mingchao, LI Yue, ZHANG Yan. Pharmacological targets and clinical application of traditional Chinese medicine and active components in the prevention and treatment for depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 467-474.
[9]	DING Lulu, GUO Jianyou. Neurobiological factors of trait anxiety and its influences on individual cognitive performance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 101-106.
[10]	WANG Sijie，ZHANG Jun，LI Qian，HUANG Hua，WANG Jingjing，ZHOU Qiong，YAO Qin. Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1070-1074.
[11]	LIN Min, SHEN Zhongxia, QIAN Mincai, CUI Lijun, REN Lie, CAI Min, SHEN Xinhua. Relationship between 5-HTT gene polymorphism and treatment response in the treatment of generalized anxiety disorder patients with anti-depressants [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 903-909.
[12]	ZHOU Yancan. Effects of agomelatine on depressive disorder and brain-derived neurotrophic factor ZHOU Yancan [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 699-703.
[13]	HU Defeng, WANG Yihu, LONG Xiaoyu, WANG Guangshui. Intervention effect of modified Ganmaidazao Tang combined with cognitive behavioral intervention on ultra-high risk for developing psychosis and the effects on cognitive function, quality of life and serum levels of 5-HT, MT and TSH [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 546-553.
[14]	CHEN Lianzhou, LI Songhua, PU Ben. Effects of aripiprazole combined with escitalopram oxalate on DA, 5-HT and cortisol in patients with severe depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 446-450.
[15]	CAI Dandan, GUI Donghui, ZHANG Jianbing, ZHOU Wenhua. Clinical efficacy of low dose risperidone combined with trazodone in the treatment of heroin addicts during detoxification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 94-98.